Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Down 7.4% in February

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) was the target of a significant decline in short interest in February. As of February 28th, there was short interest totalling 2,120,000 shares, a decline of 7.4% from the February 13th total of 2,290,000 shares. Based on an average daily trading volume, of 212,000 shares, the days-to-cover ratio is currently 10.0 days. Currently, 8.9% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IPSC. UBS Group AG bought a new position in Century Therapeutics during the 4th quarter valued at approximately $28,000. Barclays PLC raised its position in Century Therapeutics by 533.3% during the 4th quarter. Barclays PLC now owns 5,408 shares of the company’s stock valued at $28,000 after purchasing an additional 4,554 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Century Therapeutics by 27.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 4,157 shares of the company’s stock valued at $41,000 after purchasing an additional 904 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Century Therapeutics during the 4th quarter valued at approximately $41,000. Finally, SG Americas Securities LLC bought a new position in Century Therapeutics during the 4th quarter valued at approximately $53,000. Institutional investors own 35.81% of the company’s stock.

Century Therapeutics Trading Down 1.2 %

Shares of IPSC stock opened at $3.98 on Friday. The stock has a market capitalization of $234.70 million, a PE ratio of -2.02 and a beta of 0.69. Century Therapeutics has a 1-year low of $3.54 and a 1-year high of $14.02. The business has a 50-day moving average of $4.55 and a 200 day moving average of $7.74. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.44 and a quick ratio of 13.44.

Analysts Set New Price Targets

Several research firms recently commented on IPSC. EF Hutton Acquisition Co. I restated a “buy” rating and set a $16.00 target price on shares of Century Therapeutics in a research report on Thursday. Chardan Capital initiated coverage on Century Therapeutics in a report on Tuesday, December 27th. They issued a “buy” rating and a $19.00 price objective for the company. SVB Leerink cut their price objective on Century Therapeutics from $20.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, January 6th. Piper Sandler cut their price objective on Century Therapeutics from $24.00 to $14.00 and set an “overweight” rating for the company in a report on Friday, January 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective on shares of Century Therapeutics in a report on Thursday, February 9th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.13.

Century Therapeutics Company Profile

(Get Rating)

Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.